Jennifer P Hall1, Giovanni Zanotti2, Ruth Kim2, Stan P Krulewicz3, Andrea Leith1, Abigail Bailey1, Frank X Liu4, Mairead Kearney5. 1. Adelphi Real World, Bollington, Macclesfield, SK10 5JB, UK. 2. Health Economics and Outcomes Research, Pfizer, New York, NY 10017, USA. 3. Medical Affairs, Pfizer, Collegeville, PA 19426, USA. 4. Health Economics and Outcomes Research, EMD Serono, Inc., Rockland, MA 02370, USA; a business of Merck KGaA, Darmstadt, Germany. 5. Global Evidence and Value Development, Merck KGaA, 64293, Darmstadt, Germany.
Abstract
Aim: Assessing treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma clinical practice. Materials & methods: A US cross-sectional physician survey conducted February-September 2019. Results: Surveyed physicians reported first-line treatment of 445 patients involving tyrosine kinase inhibitor monotherapy (51.0%), immuno-oncology (IO/IO combination) therapy (25.8%) or other regimens (23.1%). A total of 60.9% had physician-assessed IMDC risk. Of these 61.9, 50.9 and 27.6% of patients with favorable, intermediate and poor risk, respectively, received tyrosine kinase inhibitor monotherapy. A total of 16.7, 26.9 and 34.5% of patients with favorable, intermediate or poor risk received IO/IO combination therapy. Complete/partial responses (∼35% patients) remained comparable across first-line treatments. Conclusion: Guideline-recommended therapies are not widely prescribed. Many patients experienced poor clinical outcomes highlighting a need for more effective treatments.
Aim: Assessing treatment patterns, outcomes and clinical characteristics in advanced renal cell carcinoma clinical practice. Materials & methods: A US cross-sectional physician survey conducted February-September 2019. Results: Surveyed physicians reported first-line treatment of 445 patients involving tyrosine kinase inhibitor monotherapy (51.0%), immuno-oncology (IO/IO combination) therapy (25.8%) or other regimens (23.1%). A total of 60.9% had physician-assessed IMDC risk. Of these 61.9, 50.9 and 27.6% of patients with favorable, intermediate and poor risk, respectively, received tyrosine kinase inhibitor monotherapy. A total of 16.7, 26.9 and 34.5% of patients with favorable, intermediate or poor risk received IO/IO combination therapy. Complete/partial responses (∼35% patients) remained comparable across first-line treatments. Conclusion: Guideline-recommended therapies are not widely prescribed. Many patients experienced poor clinical outcomes highlighting a need for more effective treatments.
Authors: Robert J Motzer; David F McDermott; Bernard Escudier; Mauricio Burotto; Toni K Choueiri; Hans J Hammers; Philippe Barthélémy; Elizabeth R Plimack; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Howard Gurney; Christian K Kollmannsberger; Marc-Oliver Grimm; Carlos Barrios; Yoshihiko Tomita; Daniel Castellano; Viktor Grünwald; Brian I Rini; M Brent McHenry; Chung-Wei Lee; Jennifer McCarthy; Flavia Ejzykowicz; Nizar M Tannir Journal: Cancer Date: 2022-04-05 Impact factor: 6.921